We are live on
!
Find out more
PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$970M
1-Year Est. Return
79.46%
This Fund
S&P 500
This Quarter
Est. Return
+7.79%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$453M
AUM Growth
+$57.9M
(+15%)
Cap. Flow
+$54.8M
Cap. Flow
% of AUM
12.09%
Top 10 Holdings %
Top 10 Hldgs %
36.96%
Holding
92
New
18
Increased
38
Reduced
28
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$17.1M |
| 2 |
HCA Healthcare
HCA
|
+$12.4M |
| 3 |
CVS Health
CVS
|
+$12.3M |
| 4 |
Danaher
DHR
|
+$4.2M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$3.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$7.39M |
| 2 |
DexCom
DXCM
|
+$7.21M |
| 3 |
Insulet
PODD
|
+$5.03M |
| 4 |
Arcus Biosciences
RCUS
|
+$4.64M |
| 5 |
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
|
+$4.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.63% |
| 2 | Industrials | 1.69% |
| 3 | Technology | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSLT
76
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $964K | 0.21% |
625,678
+25,678
| +4% | +$42.4K |
|
|
BLRX
77
BioLineRX
BLRX
$11.7M
| $874K | 0.19% |
10,715
+438
| +4% | +$45.7K |
|
78
Quanterix
QTRX
$139M
| $848K | 0.19% |
+20,000
| New | +$934K |
|
|
ICAD
79
DELISTED
iCAD Inc
ICAD
| $744K | 0.16% |
103,302
-21,698
| -17% | -$194K |
|
80
Zymeworks
ZYME
$1.77B
| $682K | 0.15% |
41,625
+11,625
| +39% | +$242K |
|
|
ONCT
81
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $657K | 0.15% |
14,464
-1,805
| -11% | -$121K |
|
|
MTEM
82
DELISTED
Molecular Templates, Inc.
MTEM
| $579K | 0.13% |
9,849
+405
| +4% | +$30.3K |
|
83
Vera Therapeutics
VERA
$2.16B
| $576K | 0.13% |
21,555
-4,083
| -16% | -$90.3K |
|
84
Verastem
VSTM
$629M
| $376K | 0.08% |
15,278
+628
| +4% | +$19.8K |
|
85
Amgen
AMGN
$225B
| – | – |
-20,000
| Closed | -$4.25M |
|
86
BridgeBio Pharma
BBIO
$16.4B
| – | – |
-57,978
| Closed | -$2.72M |
|
87
Gyre Therapeutics
GYRE
$706M
| – | – |
-17,793
| Closed | -$548K |
|
|
88
Humana
HUM
$46.7B
| – | – |
-19,000
| Closed | -$7.39M |
|
|
NOTV
89
DELISTED
Inotiv
NOTV
| – | – |
-97,500
| Closed | -$2.85M |
|
90
Vericel Corp
VCEL
$2.29B
| – | – |
-20,340
| Closed | -$993K |
|
|
CALA
91
DELISTED
Calithera Biosciences, Inc
CALA
| – | – |
-5,031
| Closed | -$219K |
|
|
DRNA
92
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-209,686
| Closed | -$4.23M |
|
Similar funds
LOIM
MGCM
JWM
WAM
GHC
SAM
TCCM
UIC
Parkman Healthcare Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Parkman Healthcare Partners held 92 positions worth $453M, up 15% from $395M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Parkman Healthcare Partners deployed $54.8M of net new capital in Q4 2021, opening 18 new positions and adding to 38 existing holdings. Its largest new stake was UnitedHealth: 37,823 shares worth $19M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was DexCom, an estimated $7.21M trimmed.
- Parkman Healthcare Partners's largest Q4 2021 buy was UnitedHealth: 37,823 shares worth $19M.
- Parkman Healthcare Partners added most to Danaher in Q4 2021, an estimated $4.2M increase.
- Parkman Healthcare Partners's biggest Q4 2021 reduction was DexCom, cutting an estimated $7.21M.
- Parkman Healthcare Partners fully exited Humana in Q4 2021, selling an estimated $7.39M.
- Parkman Healthcare Partners's ten largest holdings make up 37% of its $453M portfolio in Q4 2021.
- Parkman Healthcare Partners opened 18 new positions and closed 8 in Q4 2021.
- Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $453M.
Based on Parkman Healthcare Partners's 13F filing for Q4 2021, filed 11 Feb 2022.